Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.98 USD | +4.86% | +6.36% | -28.31% |
01:15am | Transcript : Immunocore Holdings plc - Special Call | |
May. 29 | Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3 | MT |
Sales 2024 * | 239M 304M | Sales 2025 * | 261M 332M | Capitalization | 1.93B 2.45B |
---|---|---|---|---|---|
Net income 2024 * | -81M -103M | Net income 2025 * | -96M -122M | EV / Sales 2024 * | 6.95 x |
Net cash position 2024 * | 263M 335M | Net cash position 2025 * | 214M 272M | EV / Sales 2025 * | 6.57 x |
P/E ratio 2024 * |
-25.3
x | P/E ratio 2025 * |
-20.3
x | Employees | 497 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.66% |
Latest transcript on Immunocore Holdings plc
1 day | +4.86% | ||
1 week | +6.36% | ||
1 month | -17.10% | ||
3 months | -27.13% | ||
6 months | -7.11% | ||
Current year | -28.31% |
Managers | Title | Age | Since |
---|---|---|---|
Bahija Jallal
CEO | Chief Executive Officer | 62 | 18-12-31 |
Brian DiDonato
DFI | Director of Finance/CFO | 57 | 20-03-31 |
John Trainer
COO | Chief Operating Officer | 50 | 23-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Perez
BRD | Director/Board Member | 59 | 19-08-31 |
John Bell
CHM | Chairman | 71 | 15-02-28 |
Bahija Jallal
CEO | Chief Executive Officer | 62 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.23% | 1,085 M€ | +9.05% | - | |
0.18% | 0 M€ | 0.00% | - | |
0.14% | 5 M€ | +15.85% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 48.98 | +4.86% | 1,184,594 |
24-05-30 | 46.71 | +2.21% | 1,058,863 |
24-05-29 | 45.7 | -1.30% | 715,637 |
24-05-28 | 46.3 | +0.54% | 1,005,798 |
24-05-24 | 46.05 | -4.02% | 5,140,250 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.31% | 2.45B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- IMCR Stock